Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines the economics of biologic drugs for...
MGA Releases Economic Impact Report for Multinational Pharmaceutical Company In a newly released report, MGA highlights the broad economic impact of Otsuka Pharmaceutical in the U.S. operations. A leader in mental health and nephrology treatments, Otsuka offers both...
New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines current trends and economics in the ophthalmology...
Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded MGA’s Alex Brill submitted a letter in response to a request for information from the Federal Trade Commission. The FTC was looking for information regarding the business practices of pharmacy benefit...
New Report from MGA Examines Impact of Rebates on Drug Pricing, Competition MGA has released a new report today, “Understanding Drug Rebates and Their Role in Promoting Competition,” authored by founder and CEO Alex Brill. Offering new analysis on the...
Patent Thickets Constrain US Biosimilars Market Alex Brill and Christy Robinson | BioProcess International Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and...
